FLX, Boston Scientific

Boston Scientific Watchman FLX demonstrates superiority to anticoagulants in study
Boston Scientific announced positive three-year primary endpoint results from a clinical trial of its Watchman FLX device.
Boston Scientific’s WATCHMAN FLX: Poised for Growth with New Trial Results and Reimbursement Code
Mizuho Securities analyst Anthony Petrone has maintained their bullish stance on BSX stock, giving a Buy rating yesterday.Don't Miss our Black
BSX Stock Gains From Positive OPTION Trial Data for WATCHMAN FLX
Boston Scientific Corporation BSX recently announced favorable three-year primary endpoint data from the OPTION global clinical trial for its WATCHMAN FLX Left Atrial Appendage Closure (“LAAC”) device.
Boston Sci stock climbs 5% on positive Watchman FLX data
Boston Scientific (BSX) stock climbed 5% after a study showed its Watchman FLX device was superior to oral anti-coagulants in reducing bleeding risks following cardiac ablation.
Buy Recommendation for Boston Scientific Driven by Promising Watchman FLX Data and Growth Prospects
Boston Scientific (BSX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Travis Steed
Abbott reports positive Amplatzer Amulet data in head-to-head trial with Boston Scientific’s Watchman
Abbott (NYSE:ABT) announced new data supporting its Amplatzer Amulet left atrial appendage (LAA) occluder system.
Pharmabiz12h
Boston Scientific WATCHMAN FLX LAAC device demonstrates superior bleeding risk reduction to OAC following a cardiac ablation in OPTION clinical trial
Boston Scientific Corporation announced positive three-year primary endpoint results from the OPTION global clinical trial of the WATCHMAN FLX Left Atrial Appendage Closure (LAAC) Device. Key ...
FierceBiotech13h
AHA 2024: Boston Scientific, Abbott tout long-term heart occluder data
Abbott’s Amulet IDE trial put its left atrial appendage closure device up against the Watchman 2.5, which was approved by the ...
GlobalData on MSN1d
Boston Scientific reports outcomes from trial of LAAC device
The trial met its primary safety and efficacy endpoints, demonstrating the device's superiority to oral anticoagulants.
Boston Scientific’s Watchman could be new option for patients post ablation: study
The trial compared the stroke prevention device for left atrial appendage closure to blood thinners in people who underwent ...
Benzinga.com1d
Why Is Medical Device Giant Boston Scientific Stock Trading Higher On Monday?
The WATCHMAN FLX device showed superior safety with 8.5% major bleeding ... following a cardiac ablation were presented ...
BioWorld2d
Boston Sci study shows Watchman Flx better OPTION than DOAC
Boston Scientific Corp.’s OPTION study demonstrated left atrial appendage closure with the Watchman Flx device reduced risk of stroke compared to management with direct oral anticoagulants or ...